April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” High-dose vitamin D and an anti-inflammatory diet may help improve symptoms in autoimmune conditions like SLE and AA.
14 citations
,
March 2025 in “Nano Today” The hydrogel dressing speeds up and improves diabetic wound healing.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
October 2012 in “Organic Process Research & Development” A new method was developed to purify finasteride for better medical use.
2 citations
,
March 2016 in “Düşünen Adam” Switching from escitalopram to duloxetine improved hair loss.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
March 2023 in “SKIN The Journal of Cutaneous Medicine”
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
April 2014 in “Investigative Ophthalmology & Visual Science”
9 citations
,
April 1987 in “International Journal of Dermatology” Stopping the depression medication improved the woman's eyebrow hair loss, and a treatment for a skin condition caused by mites was effective.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
February 2026 in “Journal of Nanobiotechnology” A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.
1 citations
,
June 2017 in “Journal of The American Academy of Dermatology” Topical treatment SM04554 safely promotes hair growth in male baldness.
3 citations
,
March 2005 in “Journal of the American Academy of Dermatology” The lotion and shampoo effectively treated scalp seborrheic dermatitis.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
19 citations
,
August 2019 in “Dermatologic therapy” Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
Melatonin can improve treatment and extend remission for certain skin conditions.
Baricitinib effectively regrows hair in severe alopecia areata cases.
Ozonized sunflower oil effectively heals small animal wounds and promotes hair growth.
27 citations
,
October 2020 in “Drugs” Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
August 2023 in “Clinical and Experimental Dermatology” The document discusses a special exam case for formulating and using systemic therapy named Athena.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
3 citations
,
November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
3 citations
,
January 2019 in “Therapeutic advances in urology” WS PRO 160 I 120 mg effectively treats urinary symptoms from BPH with good safety and tolerability.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
2 citations
,
November 2007 in “Clinics in dermatology” Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.
1 citations
,
March 2023 in “Medicine” Satoyoshi syndrome can cause eye problems like uveitis and retinal vein issues.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.